Monitoring gonadotropin-releasing hormone administration by measurement of urinary steroid conjugates.
The use of measuring urinary steroid conjugates in nontimed, randomly collected morning urine samples expressed as a function of creatinine concentration was assessed to monitor ovarian response to pulsatile administration of gonadotropin-releasing hormone in ambulatory patients. This method of evaluating ovarian steroid production provided a convenient, inexpensive, and noninvasive means of monitoring responses to gonadotropin-releasing hormone treatments and documents that clomiphene-resistant amenorrheic patients can be induced to ovulate with appropriate gonadotropin-releasing hormone therapy. Different ovarian responses in the same woman to similar doses and frequencies of gonadotropin-releasing hormone indicate that discrete adjustments of individual doses may be required to facilitate consistent ovulatory responses. The strategy presented here allows for subsequent gonadotropin-releasing hormone therapy in the individual patient to be determined by an objective and quantifiable ovarian response to an initial treatment.
D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy; D003404:Creatinine / Q000652:urine; D004967:Estrogens / Q000652:urine; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy* / Q000378:metabolism; D008597:Menstrual Cycle; D010060:Ovulation / Q000187:drug effects; D010906:Pituitary Hormone-Releasing Hormones / Q000008:administration & dosage* / Q000378:metabolism; D011276:Pregnanediol / Q000652:urine; D011863:Radioimmunoassay; D013256:Steroids / Q000652:urine*
D004967:Estrogens; D010906:Pituitary Hormone-Releasing Hormones; D013256:Steroids; D003404:Creatinine; D011276:Pregnanediol